Cargando…
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
BACKGROUND: There is an unmet need to identify markers that predict the response to nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR) was recently recognized as an indicator of a poor prognosis in patients with various cancers. In the present stu...
Autores principales: | Nakaya, Aya, Kurata, Takayasu, Yoshioka, Hiroshige, Takeyasu, Yuki, Niki, Maiko, Kibata, Kayoko, Satsutani, Naoko, Ogata, Makoto, Miyara, Takayuki, Nomura, Shosaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097082/ https://www.ncbi.nlm.nih.gov/pubmed/29442281 http://dx.doi.org/10.1007/s10147-018-1250-2 |
Ejemplares similares
-
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2017) -
Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer
por: Nakaya, Aya, et al.
Publicado: (2017) -
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018) -
Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017) -
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)